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A B S T R A C T
Dysregulation of insulin signaling pathway with reduced downstream neuronal survival and plasticity me-
chanisms is a fundamental abnormality observed in Alzheimer's disease (AD) brain. This phenomenon, known as
brain insulin resistance, is associated with poor cognitive performance and is driven by the uncoupling of insulin
receptor (IR) from its direct substrate (IRS1). Considering that Down syndrome (DS) and AD neuropathology
share many common features, we investigated metabolic aspects of neurodegeneration, i.e., brain insulin re-
sistance, in DS and whether it would contribute to early onset AD in DS population.
Changes of levels and activation of main brain proteins belonging to the insulin signaling pathway (i.e., IR,
IRS1, PTEN, GSK3β, PKCζ, AS160, GLUT4) were evaluated. Furthermore, we analyzed whether changes of these
proteins were associated with alterations of: (i) proteins regulating brain energy metabolism; (ii) APP cleavage;
and (ii) regulation of synaptic plasticity mechanisms in post-mortem brain samples collected from people with
DS before and after the development of AD pathology (DSAD) compared with their age-matched controls.
We found that DS cases were characterized by key markers of brain insulin resistance (reduced IR and in-
creased IRS1 inhibition) early in life. Furthermore, downstream from IRS1, an overall uncoupling among the
proteins of insulin signaling was observed. Dysregulated brain insulin signaling was associated with reduced
hexokinase II (HKII) levels and proteins associated with mitochondrial complexes levels as well as with reduced
levels of syntaxin in DS cases. Tellingly, these alterations precede the development of AD neuropathology and
clinical presentations in DS.
We propose that markers of brain insulin resistance rise earlier with age in DS compared with the general
population and may contribute to the cognitive impairment associated with the early development of AD in DS.
1. Background
Down syndrome (DS) is a genetic-related disorder - due to tripli-
cation of Chromosome 21 - characterized by intellectual disability and
often between ages of 40–50 years by early onset Alzheimer-like
dementia (AD). There are approximately 6 million people with DS
worldwide, most of them without a completely independent life
(Foundation, 2019). Moreover, improvements in care for children and
adults with DS have led to significant extensions in life span and quality
of life for people with (Lott and Head, 2019).
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Intellectual disability in DS is due to alterations of brain develop-
ment that can be traced back to foetal life stages. These alterations
include widespread impairments in neurogenesis, excessive numbers of
astrocytes, dendritic atrophy, and impaired connectivity (Bartesaghi
et al., 2011). These deficits are distributed throughout the brain and,
therefore, a constellation of brain functions is altered. A key challenge
for adults with DS is an increased risk of developing clinical symptoms
of AD as they age. Almost all adults with DS demonstrate AD-like
neuropathology by age 40 years. In the affected DS elderly, extensive
similarities with AD regarding clinical presentation, neuropathological
findings and participation of genetic factors justifies the designation of
AD in DS (Wiseman et al., 2015).
An increasing number of studies showed that molecules able to
regulate glucose metabolism, such as insulin, insulin-like growth factor-
1 and glucagon-like peptide-1, modulate different functions of the
cortex and hippocampus – two key areas of the brain responsible of
learning and memory – and are also involved in development and aging
processes (Arnold et al., 2018; Biessels and Reagan, 2015). Detection of
insulin in the brain reveals that the brain is a target organ for insulin.
Indeed, insulin plays several functions in the central nervous system
ranging from regulation of protein synthesis and cytoskeletal protein
expression, to neurite outgrowth, migration, and differentiation, and
synapse formation (Blazquez et al., 2014). All these functions partici-
pate in cognitive processes, including attention, executive functioning,
learning, and memory (Blazquez et al., 2014). Insulin also has the
ability to provide neuroprotection, acting mainly against apoptosis,
amyloid-β (Aβ) toxicity, oxidative stress and ischemia (Ferreira et al.,
2018).
It is now well-recognized that defects in insulin level/signaling may
have a profound impact on the central nervous system function, and
many authors have suggested that alterations of brain insulin signaling
pathway and changes in glucose metabolism may increase the risk of
developing dementia [reviewed in (Arnold et al., 2018)]. Examination
of postmortem AD and amnestic mild cognitive impairment brains
uncovered key signs of brain insulin resistance, i.e., reduced insulin
receptor (IR) and increased serine phosphorylation (inhibitory) of in-
sulin receptor substrate 1 (IRS1), particularly in the hippocampus,
cortex and hypothalamus (Biessels and Reagan, 2015; De Felice, 2013;
Tramutola et al., 2015). Higher levels of markers of insulin resistance
are associated with poorer performance on cognitive tests of episodic
and working memory, independent of the senile plaques (beta-amyloid
– Aβ) and neurofibrillary tangles (Tau) load, thus suggesting a role for
insulin signaling in neuronal functions (Biessels and Reagan, 2015).
Moreover, it is important to emphasize that brain insulin resistance and
impaired cerebral glucose metabolism are pathophysiological features
that may even precede others neuropathological alterations by several
decades (Chen and Zhong, 2013; Stanley et al., 2016). Understanding
and sequencing the cascade of changes that eventually precedes Aβ and
Tau aggregation is central to assess the “risk profile” and to identify
novel therapeutic targets that can be used for preventative interven-
tions.
No evidence is available on the expression and activation of the
members of the insulin signaling machinery in the brains of people with
DS. Given that the brains of individuals with DS share many common
neuropathological features with AD in the general population, in the
present study we hypothesized that brain insulin resistance develops in
DS as a function of age and with the development of AD neuropathology
and thus may contribute to the development of AD in DS.
2. Methods
2.1. Human subjects
Frontal cortex human brain samples were obtained from the
University of California Alzheimer's Disease Research Center (UCI-
ADRC) and the Institute for Memory Impairments and Neurological
Disorders, the Eunice Kennedy Shriver NICHD Brain and Tissue Bank
for Developmental Disorders, and the University of Kentucky
Alzheimer's disease Center. Table 1 shows the characteristics and de-
mographic data of the included cases in the study. DS cases were di-
vided into two groups, with or without sufficient pathology for a neu-
ropathological diagnosis of AD. The ages of DS cases without AD were
under 40 years, while the cases with both DS and AD were over the age
of 40 years. Likewise, controls were split into two groups: Controls
Young (Ctr Y), to compare with DS group because they are ≤45 years;
Controls Old (Ctr O), to compare with DSAD because they are older
than 45 years at death. Although the range of the age within Ctr Y and
DS subjects appears wide, this is quite similar between the two groups
of subjects [Ctr Y: 1–44 y; DS: 9–39 y (Table 1)] thus limiting the im-
pact of age when comparing DS vs Ctr Y. Moreover this in agreement
with previous studies both from our groups and others (Cenini et al.,
2012; Hamlett et al., 2017; Lott and Head, 2019; Perluigi et al., 2014;
Tramutola et al., 2017; Wilcock et al., 2015).
All the results obtained from human autopsy samples were analyzed
by considering the difference in postmortem interval (PMI) among
groups. Correlation analysis did not show any association between all
the reported measures and PMI (Supplementary Table 1). A more lim-
ited sample was available for studies of syntaxin and PSD95 protein
levels, as two samples in the DS group and 1 sample in DSAD group
were no longer available, thus sample size for these analyses was
smaller.
In some of the results showed throughout the paper there are
samples that appears to be out of the mean range. In particular for Ctr Y
and DS group, we acknowledge that these samples are neither the
younger nor the oldest. All the samples were maintained in the analysis
Table 1
Subjects demographic data.
Subjects PMI Age Sex Race Cause of death
Ctr Y 1 20 9 F African
American
Asthma
Ctr Y 2 28 13 M African
American
Accident, fire
Ctr Y 3 8 33 M Caucasian Cardiac arrythmia
Ctr Y 4 17 39 F Caucasian Car accident
Ctr Y 5 12 22 M African
American
Cardiac arrythmia
Ctr Y 6 10 11 F Caucasian Asthma
DS 1 12 2 M Caucasian Unknown
DS 2 15 23 M African
American
Pneumonia
DS 3 24 24 M Caucasian Cardiac arrythmia
DS 4 28 1 F African
American
Pneumonia
DS 5 13 44 F Caucasian Cardiac arrythmia
DS 6 12 39 F Caucasian Cancer
DS 7 10 40 M African
American
Hypertensive cardiovascular dis.
DS 8 14 20 M Indian Cardiopulmonary arrest
DSAD 1 10 66 M Unknown Cardiac arrest
DSAD 2 3.3 58 M Unknown Alzheimer disease
DSAD 3 11 61 M Unknown Unknown
DSAD 4 4.5 55 M Unknown Pneumonia
DSAD 5 3 63 F Unknown Respiratory problems
DSAD 6 6 63 F Unknown Unknown
DSAD 7 5.3 57 F Unknown Seizure disorder
DSAD 8 3 62 F Unknown Pneumonia
Ctr O 1 17 57 M Caucasian Hypertensive cardiovascular dis.
Ctr O 2 24 46 F Caucasian Bike acident
Ctr O 3 8 64 F Unknown Myocardial infarction
Ctr O 4 28 52 M Caucasian Ateriosclerotic Cardiovascular
dis.
Ctr O 5 16 55 M Caucasian Ateriosclerotic Cardiovascular
dis.
Ctr O 6 4.5 65 M Unknown Cardiac arrest
Ctr O 7 17 55 M Caucasian Car accident
Ctr O 8 2.7 67 M Unknown Cardiomyopathy
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because they are representative of the physiological variability char-
acterizing human subjects. Indeed, the complexity of DS phenotypes is
the result of significant individual variability, due to trisomy 21; thus, it
is recommended to consider this aspect in sample collection and ana-
lysis (Lott and Head, 2019).
Finally, we acknowledge that the same autopsy cases were used in
previous experiments measuring Aβ levels, p-Tau levels, total oxida-
tion, and autophagy pathway as a function of age in DS (Cenini et al.,
2012; Di Domenico et al., 2014; Perluigi et al., 2014).
2.2. Samples preparation
Total protein extracts from the frontal cortex were prepared in
radioimmunoprecipitation assay (RIPA) buffer (pH 7.4) containing Tris-
HCl (50 mM, pH 7.4), NaCl (150 mM), 1% NP-40, 0.25% sodium
deoxycholate, ethylenediamine tetraacetic acid (EDTA) (1 mM), 0.1%
sodium dodecyl sulfate (SDS), supplemented with protease inhibitors
[phenylmethylsulfonyl fluoride (PMSF, 1 mM), sodium fluoride (NaF,
1 mM) and sodium orthovanadate (Na3VO4, 1 mM)]. Before clarifica-
tion, brain tissues were homogenized by 20 passes with a Wheaton
tissue homogenizer. Brain tissues homogenates were then centrifuged at
16,000 × g for 1 h at 4 °C. The supernatant was used to determine the
total protein concentration by the Bradford assay (Pierce, Rockford, IL).
2.3. Western blot
For western blots, 20 μg of proteins were resolved on Criterion TGX
Stain-Free 4–15% 18-well gel (Bio-Rad Laboratories, #5678084) in a
Criterion large format electrophoresis cell (Bio-Rad Laboratories,
#1656001) in Tris/Glycine/SDS (TGS) Running Buffer (Bio-Rad
Laboratories, #1610772). Immediately after electrophoresis, the gel
was then placed on a Chemi/UV/Stain-Free tray and then placed into a
ChemiDoc MP imaging System (Bio-Rad Laboratories, #17001402) and
UV-activated based on the appropriate settings with Image Lab
Software (Bio-Rad Laboratories) to collect total protein load image.
Following electrophoresis and gel imaging, the proteins were
transferred via the TransBlot Turbo semi-dry blotting apparatus (Bio-
Rad Laboratories, #1704150) onto nitrocellulose membranes (Bio-Rad,
Hercules, CA, USA, #162–0115) and membranes were blocked with 3%
bovine serum albumin in 0.5% Tween-20/Tris-buffered saline (TTBS)
and incubated overnight at 4 °C with the following antibodies: anti-IRβ
(1:1000, Cell Signaling, Bioconcept, Allschwill, Switzerland, #3020),
anti-phospho(Tyr1158/1162/1163)-IRβ (1:1000, Genetex, Irvine, CA,
USA, #GTX25681), anti-IRS1 (1:1000, Cell Signaling, Bioconcept,
Allschwill, Switzerland, #3407), anti-phospho(Ser636)-IRS1 (1:500,
Santa Cruz, Santa Cruz, CA, USA, #sc-33,957), anti-phospho(Tyr632)-
IRS1 (1:500, Santa Cruz, Santa Cruz, CA, USA, #sc-17,196), anti-PTEN
(1:1000, Santa Cruz, Santa Cruz, CA, USA, #sc-7974), anti-phospho
(Ser380/Thr382/383)-PTEN (1:500, Santa Cruz, Santa Cruz, CA, USA,
#sc-101,789), anti-GSK3β (1:1000, Santa Cruz, Santa Cruz, CA, USA,
#sc-377,213), anti-phospho(Ser9)-GSK3β (1:500, Santa Cruz, Santa
Cruz, CA, USA, #sc-373,800), anti-phospho(Tyr216)-GSK3β (1:500,
Santa Cruz, Santa Cruz, CA, USA, #sc-135,653), anti-GLUT4 (1:1000,
Santa Cruz, Santa Cruz, CA, USA, #sc-53,566), anti-AS160 (1:1000,
Thermo Fischer, Waltham, MA, USA), anti-phospho(Thr642)-AS160
(1:1000, GeneTex, Irvine, CA, USA), anti-PKCζ (1:1000, Santa Cruz,
Santa Cruz, CA, USA, #sc-393,218), anti-hexokinase II (1:1000, Santa
Cruz, Santa Cruz, CA, USA, #sc-130,358), anti-APP (1:10000, Sigma-
Aldrich, St Louis, MO, USA, #A8717), anti-TNFα (1:1000, EMD
Millipore, Billerica, MA, USA, #AB1837P), anti-syntaxin (1:1000,
Genetex, Irvine, CA, USA, #GTX113559), anti-PSD95 (1:1000, abcam,
Cambridge, United Kingdom, #ab18258). For analyses of mitochon-
drial complexes, a cocktail of anitbodies against each subunit was used
(1:3000, abcam, Cambridge, United Kingdom, #ab110411). After 3
washes with Tween-20/Tris buffered saline (TTBS) buffer the mem-
branes were incubated for 60 min at room temperature with anti-
rabbit/mouse/goat IgG secondary antibody conjugated with horse-
radish peroxidase (1:5000; Sigma–Aldrich, St Louis, MO, USA).
Membranes were developed with Clarity enhanced chemiluminescence
(ECL) substrate (Bio-Rad Laboratories, #1705061) and then acquired
with Chemi-Doc MP (Bio-Rad, Hercules, CA, USA) and analyzed using
Image Lab software (Bio-Rad, Hercules, CA, USA) that permits the
normalization of a specific protein signal with the β-actin signal in the
same lane or total proteins load.
2.4. Statistical analyses
Data were calculated as a percentage of Ctr Y and are expressed as
mean ± SEM. Data were first tested for equal variance and normality
(Shapiro–Wilk test). Data were then analyzed by two-way analyses of
variance (ANOVA) with diagnostic group (DS vs Ctr) and age (Old vs
Young) as between-subject factors. Tukey's honestly significant differ-
ence (HSD) test was used for multiple post-hoc comparisons when re-
quired. All statistical tests were two-tailed and the level of significance
was set at 0.05. Correlation analyses were calculated by Pearson's rank
correlations All the analyses were performed using GraphPad Prism 7.0
software.
3. Results
3.1. Dysregulation of brain insulin signaling occurs early in DS
Changes of (i) levels and (ii) activation/inhibition state of proteins
belonging to the insulin signaling pathway were evaluated in the frontal
cortex of DS subjects before (DS, age < 40y) and after the develop-
ment of AD pathology (DSAD, age > 40y) in comparison with age-
matched controls (Ctr Y and Ctr O) (Table 1). No significant changes for
IR protein levels and activation (pIR/IR) were observed among the 4
groups (Fig. 1 A-C). Notwithstanding the lack of statistical significance,
IR protein levels showed a trend to be reduced in the younger DS
without AD cases (−50% vs Ctr Y, Fig. 1B), as previously reported in
AD (Barone et al., 2019; Batista et al., 2018; Bomfim et al., 2012;
Frolich et al., 1998; Zhao et al., 2008). However, a significantly in-
creased inhibition of IRS1 (evaluated as ratio between the two main
inhibition/activation phosphorylation sites, Ser636/Tyr632) both in DS
(+176%) and DSAD (+168%) subjects with respect to age-matched
controls (Fig. 1A,D), was observed. Increased IRS1 inhibition in DS is
mainly driven by increased Ser636 phosphorylation, since no sig-
nificant changes were observed for total IRS1 protein levels or IRS1
activation (Tyr632 phosphorylation) (Supplementary Fig. 1A-C). To
detect age and diagnostic group effects on changes in IR and IRS1 in the
frontal cortex, a 2-way ANOVA analysis was used. IR protein levels
showed a significant effect of age x diagnostic group interaction [F
(1,26) = 9.79, p= .004, Table 2]. A linear regression analysis was used
to evaluate age-associated changes in Ctr and DS populations and
showed that IR protein levels were significantly decreased with age in
Ctr subjects (Supplementary Fig. 1D), suggesting that observed losses of
IR protein in DS (Fig. 1A,B) likely recapitulate age-associated defects.
Furthermore, a deeper analysis performed by testing the association
between IR levels and age in the 4 sub-groups of subjects (Ctr Y, DS,
DSAD, Ctr O) showed that IR protein levels significantly decreased with
age in younger DS (Fig. 1E). Similar analyses performed with regard to
IR activation (pIR/IR vs age) showed no significant association (Sup-
plementary Fig. 1E,F). With regard to IRS1 inhibition (Ser636/Tyr632),
2-way ANOVA analysis revealed a main effect of diagnostic group [F
(1,26) = 25.32, p < .0001, Table 2]. A linear regression analysis
showed no significant association between IRS1 inhibition and age ei-
ther in Ctr and DS populations or in the 4 sub-groups of subjects
(Supplementary Fig. 1G,H).
Downstream from IRS1, we previously reported the hyperactivation
of phosphatydilinositol-3 kinase/protein kinase B (PI3K/Akt) axis in the
same autopsy cases used in the current study (Perluigi et al., 2014).
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Here, we extended these findings regarding alterations of brain insulin
signaling in DS population by evaluating changes of phosphatase and
tensin homolog (PTEN) and glycogen synthase-3 beta (GSK3β) proteins.
PTEN is a phosphatase, that regulates the activation of the insulin
signaling pathway by reducing the PI3K-derived phosphatidylinositol
(3,4,5)-trisphosphate (PIP3), that,in turn, promotes Akt activation
(Chen et al., 2016; Knafo and Esteban, 2017). GSK3β is one of the main
targets of Akt in response to insulin (Hermida et al., 2017), known to be
involved in neuro-protective and pro-survival mechanisms (Chong
et al., 2005). PTEN protein levels are reduced in DS with respect to Ctr
Y (−45%, Fig. 2A,B), while the evaluation of PTEN inhibitory phos-
phorylation sites reveal that PTEN is consistently activated in DS po-
pulation after the development of AD pathology (pPTEN/PTEN, −90%
in DSAD vs DS, Fig. 2A,C). With regard to GSK3β, we found a nearly
significant reduced protein levels in DS (−50%, p = .06) relative to
age-matched controls (Fig. 2A,D). GSK3β activation [evaluated as ratio
between the inhibitory and activation phosphorylation sites (Ser9/
Tyr416 ratio)] appears to be decreased following the development of
AD pathology in DS. Indeed, GSK3β is significantly inhibited in the
DSAD group with respect to both DS (+240%) and Ctr O (+362%)
(Fig. 2A,E). This findings results from increased GSK3β inhibitory
phosphorylation (Ser9) levels since no differences for the activation
phosphorylation site (Tyr416) levels were observed (Supplementary
Figs. 2A-C). A two-way ANOVA analysis reveals a significant effect of
age x diagnostic group interaction with regard to changes of PTEN
protein levels [F(1,26) = 4.65, p = .04, Table 2], while PTEN
inhibition appears to be affected by both age [F(1,26) = 14.21,
p < .001] and age x diagnostic group interaction [F(1,26) = 7.13,
p = .01] (Table 2). Reduced PTEN levels in DS seem to reproduce in
advance aging-associated alterations considering that a significant ne-
gative association between PTEN and age was found in Ctr subjects
(Fig. 2F). No significant association between PTEN inhibition (pPTEN/
PTEN) and age either in Ctr and DS populations or in the 4 sub-groups
of subjects was found (Supplementary Fig. 2D,E).
In contrast, changes of GSK3β levels [F(1,26) = 12.24, p = .001]
and activation [F(1,26) = 10.2, p= .003] are primarily associated with
DS (Table 2).
Together, these data may suggest that alterations of brain insulin
signaling occurs early in DS with respect to neurotypical controls and
before the development of AD pathology.
3.2. Altered brain insulin signaling is associated with defects in glucose
uptake in DS
To understand whether observed alterations of brain insulin sig-
naling may affect glucose uptake, we evaluated changes of the insulin-
dependent glucose transporter-4 (GLUT4) together with changes of Akt
substrate 160 (AS160) and atypical protein kinase C zeta (PKCζ), which
are responsible for translocation of GLUT4-containing vesicles to the
plasma membrane (Bogan, 2012; Kim et al., 2003; Manna and Jain,
2013). No significant changes for GLUT4 protein levels were observed
among the 4 groups (Fig. 3A,B). Levels (Supplementary Fig. 2E) and
Fig. 1. Loss of IR along with increased IRS1 inhibition in DS brain. Changes of IR protein levels and activation as well as IRS1 inhibition were evaluated in the frontal
cortex of DS individuals before (< 40 y, n = 8) and after the development of AD pathology (DSAD,> 40 y, n = 8) with respect to their age-matched controls [Ctr Y
(n = 6) and Ctr O (n = 8)]. (A) Representative western blot images and densitometric evaluation of (B) IR protein levels, (C) IR activation (pIR/IR) and (D) IRS1
inhibition (IRS1 Ser636/Tyr632 ratio). Protein levels were normalized per total protein load. IR-, and IRS1-associated phosphorylations were normalized by taking
into account the respective protein levels and are expressed as the ratio between the phosphorylated form and the total protein levels: Tyr1158/1162/1163 / IR and
(Ser636/IRS1) / (Tyr632/IRS1). All densitometric values are given as percentage of Ctr Y set as 100%. Data are presented as means± SEM, **p < .01 (Two-way
ANOVA with Bonferroni post-hoc test). (E) Linear regression analysis performed by evaluating changes of IR protein levels with respect to age in the 4 subgroups of
subjects.
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Table 2
Two-way analyses of variance (ANOVA) with diagnostic group (Ctr vs DS) and age (young vs old) as between-subject factors (n = 6/8 per group).
Parameter Diagnostic group Age Interaction
IR n.s. n.s. F(1,26) = 9.79, p = .004
pIR/IR n.s. n.s. n.s.
IRS1 n.s. n.s. n.s.
Tyr632/IRS1 F(1,26) = 3.77, p = .06 n.s. n.s.
Ser636/IRS1 F(1,25) = 26.8, p < .0001 F(1,25) = 4.25, p = .04 n.s.
Ser636/Tyr632 F(1,26) = 25.32, p < .0001 n.s. n.s.
PTEN n.s. n.s. F(1,26) = 4.65, p = .04
pPTEN/PTEN n.s. F(1,26) = 14.21, p < .001 F(1,26) = 7.13, p = .01
GSK3β F(1,26) = 12.24, p = .001 n.s. n.s.
Ser9/GSK3β F(1,26) = 7.00, p = .01 n.s. n.s.
Tyr416/GSK3β n.s. n.s. n.s.
Ser9/Tyr416 F(1,26) = 10.2, p = .003 F(1,26) = 8.11, p = .008 n.s.
GLUT4 n.s. n.s. n.s.
AS160 n.s. n.s. n.s.
Thr642/AS160 n.s. n.s. n.s.
PKCζ F(1,26) = 15.1, p = .0006 F(1,26) = 18.5, p = .0002 F(1,26) = 6.5, p = .01
HKII F(1,25) = 5.51, p = .02 n.s. n.s.
Complex II F (1, 24) = 34.75, p < .0001 n.s. F (1, 25) = 4.95, p = .03
Complex III F (1, 25) = 18.83, p < .001 n.s. F (1, 25) = 9.08, p < .01
Complex IV F (1, 25) = 12.67, p < .01 n.s. F (1, 25) = 10.8, p < .01
ATP synthase F (1, 25) = 9.41, p < .01 n.s. F (1, 25) = 8.15, p < .01
C83 n.s. n.s. F(1,25) = 5.72, p = .02
C99 n.s. F(1,25) = 6.79, p = .01 n.s.
C99/C83 n.s. n.s. F(1,25) = 4.53, p = .04
TNFα n.s. F(1,26) = 8.48, p = .007 n.s.
Syntaxin n.s. F(1,23) = 11.44, p = .002 F(1,23) = 5.13, p = .03
PSD95 n.s. F(1,23) = 5.63, p = .02 n.s.
Fig. 2. Altered PTEN and GSK3β levels and activation in DS brain. Changes of PTEN and GSK3β protein levels and activation state were evaluated in the frontal
cortex of DS individuals before (< 40 y, n = 8) and after the development of AD pathology (DSAD,> 40 y, n = 8) with respect to their age-matched controls [Ctr Y
(n=6) and Ctr O (n = 8)]. (A) Representative western blot images and densitometric evaluation of (B) PTEN protein levels, (C) PTEN inhibition (pPTEN/PTEN), (D)
GSK3β protein levels and (E) GSK3β activation (GSK3β Ser9/Tyr216 ratio). Protein levels were normalized per total protein load. PTEN-, and GSK3β-associated
phosphorylations were normalized by taking into account the respective protein levels and are expressed as the ratio between the phosphorylated form and the total
protein levels: Ser380/Thr382/383 / PTEN and (Ser9/GSK3β) / (Tyr216/GSK3β). All densitometric values are given as percentage of Ctr Y set as 100%. Data are
presented as means± SEM, *p < .05, **p < .01 and ***p < .001 (Two-way ANOVA with Bonferroni post-hoc test). (F) Linear regression analysis performed by
evaluating changes of PTEN protein levels with respect to age in Control and DS populations.
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activation (Thr642/AS160, Fig. 3A,C) of AS160 were not different as
well. In contrast, a significant reduction of PKCζ protein levels in DS
(−70%) with respect to age-matched controls was observed
(Fig. 3A,D). A linear regression analysis revealed a negative association
between PKCζ and age in Ctr subjects (Fig. 3F), highlighting loss of
PKCζ in DS as an early event in the aging process. When the same
analysis was performed by considering the 4 sub-groups separately, we
did not observe significant associations (Supplementary Fig. 2F).
We used a 2-way ANOVA analysis to determine whether age and/or
diagnostic group affects PKCζ. We found that changes of PKCζ protein
levels are dependent upon age [F(1,26) = 18.5, p = .0002], DS status
[F(1,26) = 15.1, p = .0006] and their interaction [F(1,26) = 6.5,
p = .01] (Table 2).
Overall, these data suggest that the DS brain is characterized by an
impairment of insulin-mediated glucose uptake.
3.3. Altered brain insulin signaling is associated with defects in brain energy
metabolism in DS
We hypothesized that defects of the insulin signaling pathway and
glucose uptake were associated with an impaired brain energy meta-
bolism. Thus, we evaluated changes of hexokinase-II (HKII) protein
levels along with changes of mitochondrial complexes and ATP syn-
thase levels. HKII is a rate-limiting enzyme in glucose metabolism,
whose expression normally increases in response to insulin via Akt
(Burcelin et al., 1993; Chehtane and Khaled, 2010; Culbert and Tavare,
2002; Duarte et al., 2008; Katzen, 1966; Katzen et al., 1970; Osawa
et al., 1996; Printz et al., 1993). Our results show a significant reduction
of HKII protein levels in DS with respect to Ctr Y (−53%, Fig. 3E). A
two-way ANOVA analysis highlights that observed differences are
mainly due to an effect of diagnostic group [F(1,25) = 5.51, p = .02,
Table 2] with DS showing lower levels of HKII. With regard to mi-
tochondria, we were able to detect measurable protein levels of all the
complexes (II, III and IV) except complex I. We found reduced complex
II levels in DS with respect to Ctr Y that were close to significance
(−40%, p = .07, Fig. 4A,C). All the mitochondrial complexes were
significantly reduced in the DSAD group relative to Ctr O (Complex II:
−80%; Complex III: −130%; Complex IV: −260%) (Fig. 4A-E). Also,
ATP synthase levels were significantly reduced in DSAD group with
repsect to age-matched controls (−120%, Fig. 4A,F). A two-way
ANOVA analysis highlights that differences primarily driven by lower
levels being observed in DS as well as an interaction with age (Table 2).
Together, these observations highlight that the DS brain is char-
acterized by an impairment of proteins involved in brain energy me-
tabolism, which becomes consistent with the development of AD pa-
thology.
3.4. Altered brain insulin signaling is associated with an increased
amyloidogenic cleavage of APP and a rise of TNFα levels in DS
DS is characterized by the triplication of the APP gene that favors
the amyloidogenic pathway in the brain (Lott and Head, 2019). In
addition, an increase in amyloidogenic APP processing was associated
with brain insulin resistance in AD (de la Monte, 2012; Rivera et al.,
2005; Steen et al., 2005; Talbot et al., 2012; Triani et al., 2018).
Therefore, we sought to evaluate whether a defective APP cleavage also
characterizes our cohort of subjects. We evaluated APP C83 and C99 C-
terminal fragments, which result from the cleavage of APP by alpha-
secretase (non-amyloidogenic) and beta-secretase (amyloidogenic), re-
spectively (Chen and Mobley, 2019).
Our results show no significant changes in the levels of C83 or C99
levels across the 4 groups of subjects (Fig. 5A-C). Examination of the
percentage of C99 to C83 ratio, showed higher C99/C83 ratios in DS vs
Ctr Y groups (+75%, p = .08, Fig. 5D) and in Ctr O vs Ctr Y groups
(+120%, p = .07, Fig. 5D). A two-way ANOVA analysis revealed a
main effect of age x diagnostic group interaction with regards to
changes in the C99/C83 ratio [F(1,25) = 4.53, p = .04] (Table 2). A
linear regression analysis shows that the percentage of the C99/C83
ratio increases with age in Control subjects (p = .008, Supplementary
Fig. 3), suggesting again that the observed trend in DS could reflect
defects associated with an aging process. Furthermore, when we looked
at the 4 groups separately, the contribution of age appears to be pri-
marily within the DS group in cases below the age of 40 years (Fig. 5E).
When the C99/C83 ratio and age are analyzed in this subgroup of
subjects there is a significant increase in the C99/C83 ratio with age
(p = .03).
Fig. 3. DS brain shows alterations of proteins nor-
mally regulating glucose uptake and metabolism.
Downstream from IR/IRS1 alterations of proteins
normally favoring glucose uptake in response to in-
sulin were evaluated in the frontal cortex of DS in-
dividuals before (< 40 y, n = 8) and after the de-
velopment of AD pathology (DSAD,>40 y, n = 8)
with respect to their age-matched controls [Ctr Y
(n = 6) and Ctr O (n = 8)]. (A) Representative
western blot images and densitometric evaluation of
(B) GLUT4 protein levels, (C) AS160 activation
(Thr642/AS160) and (D) PKCζ protein levels.
Protein levels were normalized per total protein
load. AS160-associated phosphorylation was nor-
malized by taking into account the respective protein
levels and is expressed as the ratio between the
phosphorylated form and the total protein levels:
Thr642/AS160. All densitometric values are given as
percentage of Ctr Y set as 100%. Data are presented
as means± SEM, *p < .05 and **p < .01 (Two-
way ANOVA with Bonferroni post-hoc test). (E)
Linear regression analysis performed by evaluating
changes of PKCζ protein levels with respect to the
age in Control and DS populations.
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Furthermore, levels of TNFα, a pro-inflammatory cytokine known to
favor IRS1 phosphorylation on Ser636 (and thus inhibition) in AD
(Bomfim et al., 2012; Lourenco et al., 2013) were evaluated. TNFα
levels were significantly elevated in DS with respect to Ctr Y (+168%,
Fig. 5F,G). A consistent elevation of TNFα also occurs in Ctr O vs Ctr Y
(+680%, Fig. 5F,G). A two-way ANOVA showed a main effect of age [F
(1,26) = 8.48, p= .007]. A linear regression analysis further highlights
a significant association for increased TNFα levels and age in Ctr sub-
jects (Fig. 5H).
3.5. Altered brain insulin signaling is associated with loss of synaptic
proteins early in DS
Brain insulin resistance was reported to impair synaptic plasticity
and thus favoring learning and memory impairment in AD (Arnold
et al., 2018). To check whether alterations of brain insulin signaling
also were associated with synaptic defects in DS, changes of two main
synaptic proteins, i.e., syntaxin (pre-synaptic) and PSD95 (post-sy-
naptic) were evaluated.
Our results show a significant reduction for syntaxin protein levels
in Ctr O vs Ctr Y (Fig. 6A,B). DS cases show an average reduction of
about 60% with respect to Ctr Y, which was nearly to significance
(p = .06, Fig. 6A,B). No significant changes for PSD95 were observed
across all groups (Fig. 6A,C). A two-way ANOVA analysis shows that
changes observed for syntaxin were affected both by age [F
(1,23) = 11.44, p = .002] and age x diagnostic group interaction [F
(1,23) = 5.13, p = .03], while the overall differences observed for
PSD95 are mainly due to an effect of age [F(1,23) = 5.63, p = .02]
(Table 2). Syntaxin levels are reduced with age in Ctr subjects (Fig. 6D),
further suggesting that lower syntaxin protein levels observed in DS
represent an early defect.
Because most of the observed changes occur early in DS even before
the development of AD pathology, we looked for any possible asso-
ciation between alterations of brain insulin signaling proteins and
changes of syntaxin or PSD95 between Ctr Y and DS. As shown in
Table 3, both syntaxin and PSD95 positively correlate with IR, IRS1,
GSK3β, AS160 as well as proteins involved in brain energy metabolism
(HKII, Complexes II-IV). In contrast, there were no significant correl-
tions found with TNFα or APP C-terminal fragments (Table 3).
Hence, these results are suggestive of the hypothesis that alterations
of brain insulin signaling are associated with loss of synaptic proteins
early in DS.
4. Discussion
Brain insulin resistance may precede the appearance of AD neuro-
pathology, thus contributing to the long preclinical period during which
often only subtle clinical symptoms are evident (Arnold et al., 2018). In
particular, insulin normally mediates fundamental actions in the brain
ranging from the regulation of cellular metabolism to the promotion of
synaptic plasticity involved in learning and memory functions (Arnold
et al., 2018).
Our results highlight for the first time that markers of brain insulin
resistance, i.e., reduced IR and increased IRS1 inhibition, are evident in
DS brain even before the development of AD pathology. These data are
particularly helpful to better understand the molecular mechanisms
associated with intellectual disability, as well as the early onset of AD in
people with DS (Lott and Head, 2019). Remarkably, similar to previous
observations in AD (Talbot et al., 2012; Tramutola et al., 2015), DS
brain shows at a young age an overall uncoupling of the members of
insulin signaling, as indicated by the inhibition of IRS1 but increased
activation of the PI3K/Akt axis (Perluigi et al., 2014) along with loss of
Akt-mediated regulation of: (i) GSK3β inhibition (no changes); (ii)
AS160 activation (no changes); (iii) PKCζ levels (reduced); and (iv)
HKII (reduced) levels (Fig. 7).
Upstream in the pathway, reduction of IR levels in young DS was
observed, that is further exacerbated as function of age. This event
appears to be a feature of DS brain and might reflect ongoing neuro-
pathological changes normally associated with aging and/or neurode-
generation. Indeed, similar changes were observed in Ctr subjects with
age. Furthermore, reduced IR levels were previously reported to be
associated with the development of AD neuropathology (Barone et al.,
2019; Batista et al., 2018; Bomfim et al., 2012; Frolich et al., 1998;
Zhao et al., 2008). Nevertheless, loss of IR is not evident in the brain of
DS subjects who developed AD (DSAD group). Rather, we observed
increased IRS1 inhibition both in DS and DSAD suggesting that brain
insulin resistance develops in young DS and persists with the develop-
ment of AD pathology. Intriguingly, in this study we strengthened the
Fig. 4. DS brain shows early alterations of proteins
regulating energy metabolism. Changes in levels of
HKII and mitochondrial complexes were evaluated in
the frontal cortex of DS individuals before (< 40 y,
n = 8) and after the development of AD pathology
(DSAD,>40 y, n = 8) with respect to their age-
matched controls [Ctr Y (n = 6) and Ctr O (n = 8)].
(A) Representative western blot images and densi-
tometric evaluation of (B) HK II, (C-E)mitochondrial
complexes and (E) ATP synthase protein levels.
Protein levels were normalized per total protein
load. All densitometric values are given as percen-
tage of Ctr Y set as 100%. Data are presented as
means± SEM, *p < .05 and **p < .01 (Two-way
ANOVA with Bonferroni post-hoc test).
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hypothesis that DS brain early shows signs of brain insulin resistance.
Indeed, in a previous study from our group performed on the same
cohort of subjects we observed increased IRS1 Ser307 phosphorylation
both in DS and DSAD (Perluigi et al., 2014). Here, we looked at other
two sites, specifically Tyr632 and Ser636, which, other than Ser307,are
the most studied residues implicated in the activation and inhibition of
IRS1, respectively (Copps and White, 2012). The reason is that IRS1
possesses multiple phosphorylation sites normally regulating its acti-
vation (in response to IR) or its inhibition (Copps and White, 2012) and
therefore increasing the experimental observations about the phos-
phorylation state of these amino acidic residues could provide a better
image of the activation or inhibition of IRS1. Our results clearly show
that Ser636 phosphorylation significantly increases in DS and DSAD
without consistent changes of Tyr632, thus confirming that IRS1 is
inhibited in DS brain before and after the development of AD pa-
thology.
Taking in mind that inhibition of IRS1 is responsible for the un-
coupling between IR and IRS1, it is conceivable that brain cells in DS
are unresponsive to the effects on insulin. Under physiological condi-
tions insulin enhances neurite outgrowth, modulates catecholamine
release and uptake, regulates trafficking of ligand-gated ion channels,
regulates expression and localization of GABA, N-methyl-D-aspartate
(NMDA) and α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid
(AMPA) receptors and modulates activity-dependent synaptic plasticity
[that is, long-term potentiation (LTP) and long-term depression (LTD)]
(Arnold et al., 2018; Spinelli et al., 2019). In addition, insulin has a
crucial role in the development and maintenance of excitatory synapses
and has been shown to promote dendritic spine formation and ex-
citatory synapse development (Arnold et al., 2018; Spinelli et al.,
2019). Finally, by inhibiting apoptosis insulin promotes neuronal sur-
vival (Arnold et al., 2018; Spinelli et al., 2019). Hence, we hypothesize
that development of brain insulin resistance in DS impairs all these
functions and contributes to the development of AD pathology.
From a molecular point of view, these processes are mediated by the
PI3K/Akt axis downstream from IRS1 (Arnold et al., 2018; Butterfield
et al., 2014a; Haeusler et al., 2018). An intriguing aspect is that despite
increased IRS1 inhibition, a hyperactivation of the PI3K/Akt axis was
observed in the same DS autopsy cases (Perluigi et al., 2014), further
supporting the hypothesis of an uncoupling among the proteins of the
insulin signaling. Results from the current study might provide novel
insights to explain this phenomenon. Specifically, we found reduced
activation of PTEN in young DS, as a result of both reduced protein
Fig. 5. Increased levels of APP cleavage products
and TNFα in DS brain. APP C-terminal fragments
(C83 and C99) and TNFα levels were evaluated in
the frontal cortex of DS individuals before (< 40 y,
n = 8) and after the development of AD pathology
(DSAD,>40 y, n = 8) with respect to their age-
matched controls [Ctr Y (n = 6) and Ctr O (n = 8)].
(A) Representative western blot images and densi-
tometric evaluation of (B) C83 (product from α-se-
cretase-mediated cleavage, non-amyloidogenic), (C)
C99 (product from β-secretase-mediated cleavage,
amyloidogenic) and (D) C99/C83 ratio. (E) Linear
regression analysis performed by evaluating changes
of C99/C83 ratio with respect to the age in the 4
subgroups of subjects. (F) Representative western
blot images and densitometric evaluation of (G)
TNFα levels. (H) Linear regression analysis per-
formed by evaluating changes of TNFα protein levels
with respect to age in Control and DS populations.
Protein levels were normalized per total protein
load. All densitometric values are given as percen-
tage of Ctr Y set as 100%. Data are presented as
means± SEM, *p < .05 (Two-way ANOVA with
Bonferroni post-hoc test).
A. Tramutola, et al. Neurobiology of Disease 137 (2020) 104772
8
levels and increased inhibition, that agree with the observed hyper-
activation of Akt, likely due to an accumulation of PIP3. Conversely, in
DSAD subjects we observed increased PTEN activation along with
sustained Akt activation, which may be the result of chronically im-
paired pathways in DSAD (Lott and Head, 2019). Observed alterations
for PTEN agree with its role in synaptic plasticity; indeed, phosphor-
ylation of a cluster of Ser/Thr residues (amino acids 380–385) on the C-
terminal tail serves to alter the conformational state of PTEN from an
open active state to a closed inhibited state. In addition to inhibiting
PTEN phosphatase activity, phosphorylation also precludes the ex-
posure of the PDZ domain (localized in the C-terminal fragment),
through which PTEN interacts with a number of proteins involved in
synaptic plasticity mechanisms (Chen et al., 2016; Knafo and Esteban,
2017; Vazquez et al., 2001). In particular, it was reported that PTEN
interacts with and regulates the NMDA receptor during LTD (Jurado
et al., 2010; Knafo et al., 2017). Paradoxically, Aβ triggers a PDZ-de-
pendent recruitment of PTEN (meaning reduced PTEN phosphoryla-
tion) into the postsynaptic compartment along with a sustained LTD,
ultimately resulting in impaired synaptic plasticity processes in AD
(Jurado et al., 2010; Knafo et al., 2017). In light of these considerations
and noting the imbalance between LTP and LTD previously observed in
animal models of DS (Roncace et al., 2017; Schulz et al., 2019; Tovar
et al., 2018), we hypothesize that loss of PTEN in young DS and hy-
peractivation of PTEN (less phosphorylated) in DSAD, both contribute
to synaptic defects observed in DS.
The hypothesized uncoupling is further evident when we examined
GSK3β. Hyper-active Akt is not associated with a significant inhibition
of GSK3β in young DS, while the opposite is found in DSAD. These
observations are in line with our previous data collected in post-mortem
brain from mild cognitive impairment (MCI) and AD subjects, in which
we identified an early phase characterized by the increased activation
of GSK3β independently from Akt (in MCI), followed by a late phase
when the inhibition of GSK3β was prominent and was associated with
increased Akt activation (in AD) (Sharma et al., 2019; Tramutola et al.,
2015). In both cases, the impairment of GSK3β parallels increased Tau
phosphorylation (Griffin et al., 2005; Medina et al., 2011; Nicolia et al.,
2017; Pei et al., 1999; Pei et al., 2003; Sharma et al., 2019; Tramutola
et al., 2015; Yarchoan et al., 2014). Furthermore, defects in GSK3β
activation were reported to alter neuronal survival and synaptic plas-
ticity mechanisms, thus contributing to the development of AD neuro-
pathology (Aceto et al., 2019; Anderton et al., 2001; Arnold et al., 2018;
Mandelkow et al., 1992; Pei et al., 1999; van der Heide et al., 2005).
Interestingly, early Tau pathological changes were observed in DS
(Hamlett et al., 2017; Head et al., 2003), with subsequent findings of
aggregated Tau into neurofibrillary tangles (NTFs) (Hof et al., 1995;
Hyman et al., 1995; Mann and Esiri, 1989; Mann et al., 1990), which
show a higher density with respect to AD (Hof et al., 1995; Lott and
Head, 2019). A pivotal role for dual-specificity tyrosine-phosphoryla-
tion regulated kinase 1A (DYRK1A) and RCAN proteins in favoring Tau
Fig. 6. Loss of synaptic proteins DS brain. Changes of syntaxin (pre-synaptic) and PSD95 (post-synaptic) protein levels were evaluated in the frontal cortex of DS
individuals before (< 40 y, n = 6) and after the development of AD pathology (DSAD,> 40 y, n = 7) with respect to their age-matched controls [Ctr Y (n = 6) and
Ctr O (n = 8)]. (A) Representative western blot images and densitometric evaluation of (B) syntaxin and (C) PSD95. (D) Linear regression analysis performed by
evaluating changes of syntaxin protein levels with respect to age in Control and DS populations. Protein levels were normalized per total protein load. All densi-
tometric values are given as percentage of Ctr Y set as 100%. Data are presented as means± SEM, *p < .05 (Two-way ANOVA with Bonferroni post-hoc test).
Table 3
Significant Pearson correlations between syntaxin or PSD95 protein levels and
proteins of the insulin signaling pathway found in young subjects (Ctr Y and
DS).
Protein Syntaxin PSD95
r= p= r= p=
IR 0.66 0.03 0.61 0.05
IRS1 0.58 0.06 0.61 0.04
GSK3β 0.67 0.02 0.68 0.02
AS160 0.80 0.003 0.81 0.002
HKII 0.66 0.03 0.60 0.06
Complex II 0.83 0.003 0.74 0.01
Complex III 0.70 0.02 0.72 0.01
Complex IV 0.72 0.01 0.78 0.007
TNFα 0.33 0.41 0.12 0.77
C83 0.06 0.84 0.05 0.88
C99 0.09 0.78 0.13 0.70
C99/C83 0.09 0.79 0.13 0.70
A. Tramutola, et al. Neurobiology of Disease 137 (2020) 104772
9
phosphorylation in DS was reported (Lott and Head, 2019). Our find-
ings further support a role for impaired brain insulin signaling, which
could favor increased Tau phosphorylation through GSK3β early in DS
brain. As we previously reported in the same autopsy cases used in the
current work (Perluigi et al., 2014), increased Tau Ser404 phosphor-
ylation [specific target for GSK3β activity (Hanger and Noble, 2011;
Leroy et al., 2010)] in young DS and DSAD subjects was evident.
Altered brain insulin signaling also impairs glucose uptake in DS. In
particular, our data suggest the existence of defects in the mechanisms
responsible for GLUT4 translocation to the plasma membrane. Although
most glucose uptake in neurons occurs via GLUT3 (Duelli and
Kuschinsky, 2001), insulin-regulated GLUT4 is also co-expressed with
GLUT3 in brain regions related to cognitive behavior (Apelt et al.,
1999). Activation by insulin induces GLUT4 translocation to the neu-
ronal cell membrane via an Akt-dependent mechanism (Grillo et al.,
2009; McEwen and Reagan, 2004) and is thought to improve glucose
flux into neurons during periods of high metabolic demand, such as
learning (Pearson-Leary and McNay, 2016). We found that both AS160
and PKCζ - that normally regulate translocation of GLUT4-containing
vesicles to the plasma membrane (Bogan, 2012; Kim et al., 2003;
Manna and Jain, 2013) – do not correlate with increased Akt activation
in DS. We found reduced PKCζ protein levels early in DS. This is an
intriguing result because in addition to mediating GLUT4 translocation
in response to insulin, PKCζ also contributes to the maintenance of LTP
in neurons thus maintaining long-term memory (Sacktor and Hell,
2017). This occurs mainly through a PKCζ cleavage products known as
PKMζ, which is autonomously active because it lacks the autoinhibitory
pseudosubstrate in the ζ regulatory domain (Hernandez et al., 2003;
Sacktor and Hell, 2017; Sacktor et al., 1993). Therefore, significantly
reduced PKCζ protein levels early in DS could impair neuronal func-
tions through both defects in glucose uptake as well as directly at the
levels of the synaptic cleft.
Reduced glucose utilization mainly results from defects of the gly-
colytic pathway and mitochondrial respiration. Our results show re-
duced HKII protein levels in young DS, that coupled with impaired
GLUT4 translocation, may strengthen the role for metabolic defects in
the development of AD-like neurodegeneration in DS. HKII is a con-
stitutively active kinase, which possesses pro-survival effects and whose
expression undergoes dynamic changes in various diseases (Roberts and
Miyamoto, 2015). Activation of the Akt/mTOR axis in response to in-
sulin was demonstrated to increase HKII protein levels (Burcelin et al.,
1993; Chehtane and Khaled, 2010; Culbert and Tavare, 2002; Duarte
et al., 2008; Katzen, 1966; Katzen et al., 1970; Osawa et al., 1996;
Printz et al., 1993). Hence, our current and previous results show re-
duced HKII protein levels in spite of the hyper-activation of the Akt/
mTOR axis early in DS, further supporting the idea of a general un-
coupling between the insulin signaling pathway and energy metabolism
in DS. The reduced glycolytic flux is also coupled with reduction of
protein levels of respiratory chain complexes, which suggest reduced
oxidative metabolism in the mitochondria in DSAD. These results are in
agreement with our previous studies showing by redox proteomics the
irreversible oxidative modification of enzymes involved in energy me-
tabolism (i.e. glyceraldehyde 3-phosphate dehydrogenase (GAPDH),
enolase, malate dehydrogenase, creatine kinase, ATP synthase), that
likely impairs their activity, both in DS and AD post mortem brain
(Barone et al., 2017; Butterfield et al., 2014b).
Moreover, alterations of brain insulin signaling in DS parallel in-
creased APP cleavage and TNFα levels, found to favor the development
of brain insulin resistance in AD (Bomfim et al., 2012; De Felice et al.,
2009; de la Monte, 2012; Lourenco et al., 2013; Rivera et al., 2005;
Steen et al., 2005; Talbot et al., 2012). With regard to the accumulation
of AD neuropathological hallmarks in DS, defects of autophagy process
were reported to have a role (Ahmed et al., 2013; Bordi et al., 2019;
Colacurcio et al., 2018; Perluigi et al., 2014). Our group showed the
hyper-activation of the PI3K/Akt axis along with increased mTOR ac-
tivation and reduced LC3 II/I levels in the frontal cortex of both DS and
DSAD subjects (Perluigi et al., 2014). In addition, we found that soluble
and insoluble Aβ peptide and oligomers increase as a function of age in
the brain of DS individuals (Cenini et al., 2012). Similar observations
were obtained for p-Tau (Perluigi et al., 2014). All the above-mentioned
Fig. 7. Schematic representation of insulin signaling
pathway with highlighted proteins found to be early
altered in DS. Under physiological conditions, the
activation of insulin signaling requires the binding of
insulin to the insulin receptor (IR), which auto-
phosphorylates on Tyr residues (e.g., Tyr1158/
1162/1163) and promotes the receptor tyrosine ki-
nase-mediated phosphorylation of its substrate
(IRS1) on specific Tyr residues (e.g. 632). Once ac-
tivated, IRS1 works as a scaffold protein, driving the
activation of the PI3K/Akt axis, that is critical for
linking upstream effectors (IR and IRS1) with
downstream proteins mediating insulin neurotrophic
outcomes. Activation of the PI3K/Akt axis is regu-
lated by the phosphatase PTEN, which reduces PIP3
levels required for Akt activation as well as for in-
creasing the expression of PKCζ. Akt promotes the
phosphorylation of several targets among which are:
(1) GSK3β (on Ser9, inhibitory site) and (2) AS160
(on Thr642, activating site). This latter, together
with PKCζ, are responsible for the translocation of
GLUT4-containing vesicles to the plasma membrane
to mediate glucose uptake. Furthermore, Akt stimu-
lates the upregulation of HKII, which is a pivotal
enzyme involved in glucose metabolism and thus
energy production. During the development of brain insulin resistance, a dysregulation of a number of these proteins was observed. In particular, the brain insulin
resistance phenomenon shows key markers such as reduced IR protein levels and/or increased IRS1 inhibitory phosphorylation levels (e.g., Ser636), that are
responsible for the uncoupling between IR and IRS1. As a result, despite that insulin binds to IR, reduced activation of its downstream effectors was found. TNFα was
reported to favors IRS1 inhibition. Moreover, brain insulin resistance was associated with an increased amyloidogenic pathway, with alterations of proteins asso-
ciated with synaptic plasticity and with reduced energy metabolism, that taken together contribute to the development of AD pathology (highlighted in red circles).
For proteins analyzed in the current and previous study (Perluigi et al., 2014): blue dotted lines (reduced levels); red lines (increased levels). (For interpretation of the
references to colour in this figure legend, the reader is referred to the web version of this article.)
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analyses were performed in the same autopsy cases used in the current
study, thus highlighting that brain insulin resistance is associated with
defects of autophagic flux that finally result in the accumulation of AD
neuropathological hallmarks early in DS. In support of this hypothesis,
we found that intranasal administration of rapamycin (a well-known
inhibitor of mTOR) in a mouse model of DS rescue mTOR hyper-acti-
vation and reduces APP cleavage products in the brain (Di Domenico
et al., 2019; Tramutola et al., 2018).
As reported in AD, increased Aβ levels and defects of brain insulin
signaling show a mutual interaction. In particular, it was proposed that,
as in a vicious cycle, brain insulin resistance favors the production and
accumulation of Aβ (de la Monte, 2012; Rivera et al., 2005; Steen et al.,
2005; Talbot et al., 2012; Triani et al., 2018), whereby increased Aβ
generation further exacerbates brain insulin resistance through dif-
ferent mechanisms including either reduced IR levels or increased
TNFα-mediated inhibition of IRS1 (Bomfim et al., 2012; De Felice et al.,
2009; Lourenco et al., 2013). Our findings agree with this paradigm
since DS brain is characterized by a significant cleavage of APP and by a
pro-inflammatory state (Lott and Head, 2019; Nistor et al., 2007;
Wilcock et al., 2015), which could contribute to the observed reduced
IR levels and increased IRS1 inhibition, respectively. However, we
cannot precisely determine “who does what”. Notwithstanding this
concern, the present collected data provide for the first time evidence
that alterations of brain insulin signaling parallel the accumulation of
AD neuropathological hallmarks in DS and that this is already evident
in young DS subjects.
Finally, we acknowledge that all the above reported alterations are
associated with loss of synaptic proteins, mainly syntaxin, which nor-
mally regulates neurotransmitter-containing vesicles exocytosis at the
pre-synaptic level (Vardar et al., 2016). Loss of syntaxin severely
compromised neuronal viability in vivo and in vitro, indicating an
obligatory role of syntaxin for maintenance of developing and mature
neurons (Vardar et al., 2016). This aspect appears of interest due to the
observation that DS brain morphology continue to diverge compared
with typically developing individuals (Lott, 2012). In particular, cor-
tical layer thickness, dendritic branching, synapse formation, brain size
and overall brain weight are all reduced (Aziz et al., 2018). Further, as
explained above insulin signaling contributes to the maintenance of
synapses (Arnold et al., 2018), thereby supporting the notion that de-
fects of brain insulin signaling likely contribute to synaptic defects
observed in DS subjects.
In conclusion, data reported in the current paper highlight that DS
subjects show signs of brain insulin resistance early in life. These al-
terations resemble those previously described for subjects developing
AD supporting a role for alterations of brain insulin signaling pathway
in the development of AD in DS (Fig. 7).
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